April 26, 2018
InSysBio LLC (www.insysbio.com) – pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development – announced today further collaboration with GSK - one of the world’s leading research-based pharmaceutical and healthcare companies - to expand the previously developed QSP model of asthma.
The companies together have constructed a complex asthma model which facilitated the investigation of novel medicines and combination therapy scenarios. GSK has chosen InSysBio as a partner to implement a further expansion of the existing model. This will include new targets and clinical trial data to be able simulate more asthma treatment scenarios.
“We chose to work with InSysBio because of their rich experience in QSP modeling and fundamental knowledge in the field. Through this partnership, we hope to continue to improve drug development in asthma”, David Fairman, Senior Director Clinical Pharmacology Modelling and Simulation, GSK, Lourdes Cucurull-Sanchez, Manager Target Sciences, GSK.
“We are very pleased that GSK decided to continue work with us. It means InSysBio has shown itself as a partner with significant expertise and strength in QSP”, Oleg Demin Jr, Head of Business Development, InSysBio.
About InSysBio
InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published a lot of scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | July 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
| ||
|
6
1.
06 Jul 2020 17:37
InSysBio to announce the launch of its new tool Heta compiler
Heta compiler has been published on GitHub as an OpenSource
(Moscow-06.07.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents Heta compiler which is a tool for the development of Quantitative Systems Pharmacology and Systems Biology platforms. Particularly, it allows combining modules written in different formats like: Heta language code, Excel sheets, JSON, YAML formatted structures, SBML and transforming them into the dynamic models of different formats.
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
1.
27 Jul 2020 11:45
InSysBio to evolve its Open Source QSP model of COVID-19
InSysBio has presented a new portion of results in the framework of development of COVID-19 QSP model.
2.
27 Jul 2020 16:42
InSysBio to present its posters at AAIC 2020 Virtual Event
InSysBio announces its participation in AAIC 2020 Virtual Event. Alzheimer's Association International Conference is held virtually on July 27-31. InSysBio team presents two posters within its frames
|
28
|
29
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
